189 related articles for article (PubMed ID: 16874486)
1. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models.
Lo KM; Lan Y; Lauder S; Zhang J; Brunkhorst B; Qin G; Verma R; Courtenay-Luck N; Gillies SD
Cancer Immunol Immunother; 2007 Apr; 56(4):447-57. PubMed ID: 16874486
[TBL] [Abstract][Full Text] [Related]
2. The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Fallon J; Tighe R; Kradjian G; Guzman W; Bernhardt A; Neuteboom B; Lan Y; Sabzevari H; Schlom J; Greiner JW
Oncotarget; 2014 Apr; 5(7):1869-84. PubMed ID: 24681847
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.
Fallon JK; Vandeveer AJ; Schlom J; Greiner JW
Oncotarget; 2017 Mar; 8(13):20558-20571. PubMed ID: 28423552
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.
Carnemolla B; Borsi L; Balza E; Castellani P; Meazza R; Berndt A; Ferrini S; Kosmehl H; Neri D; Zardi L
Blood; 2002 Mar; 99(5):1659-65. PubMed ID: 11861281
[TBL] [Abstract][Full Text] [Related]
5. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties.
Gafner V; Trachsel E; Neri D
Int J Cancer; 2006 Nov; 119(9):2205-12. PubMed ID: 16823838
[TBL] [Abstract][Full Text] [Related]
6. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.
Morillon YM; Su Z; Schlom J; Greiner JW
J Immunother Cancer; 2019 Jun; 7(1):150. PubMed ID: 31186063
[TBL] [Abstract][Full Text] [Related]
7. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
8. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
9. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.
Paoloni M; Mazcko C; Selting K; Lana S; Barber L; Phillips J; Skorupski K; Vail D; Wilson H; Biller B; Avery A; Kiupel M; LeBlanc A; Bernhardt A; Brunkhorst B; Tighe R; Khanna C
PLoS One; 2015; 10(6):e0129954. PubMed ID: 26091536
[TBL] [Abstract][Full Text] [Related]
10. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abstract] [Full Text] [Related]
12. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
13. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
Peng LS; Penichet ML; Morrison SL
J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice.
Nilsson F; Kosmehl H; Zardi L; Neri D
Cancer Res; 2001 Jan; 61(2):711-6. PubMed ID: 11212273
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
De Luca R; Neri D
Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
[TBL] [Abstract][Full Text] [Related]
16. A high-affinity human antibody that targets tumoral blood vessels.
Tarli L; Balza E; Viti F; Borsi L; Castellani P; Berndorff D; Dinkelborg L; Neri D; Zardi L
Blood; 1999 Jul; 94(1):192-8. PubMed ID: 10381513
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3).
Peng LS; Penichet ML; Dela Cruz JS; Sampogna SL; Morrison SL
J Interferon Cytokine Res; 2001 Sep; 21(9):709-20. PubMed ID: 11576465
[TBL] [Abstract][Full Text] [Related]
18. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo.
Stallmach A; Marth T; Weiss B; Wittig BM; Hombach A; Schmidt C; Neurath M; Zeitz M; Zeuzem S; Abken H
Gut; 2004 Mar; 53(3):339-45. PubMed ID: 14960512
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]